In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

GlaxoSmithKline, and Novartis. According to TipRanks, Welford has an average return of 4.4% and a 52.89% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy ...

SLE is a chronic and complex heterogeneous autoimmune disease in which the immune system dysfunctions and inappropriately ...

“If the GSK saga is a good parallel, then AstraZeneca’s China business could be in for retraction over the next 1-2 years,” ...

The firm's commentary highlighted the ongoing investigation into certain AstraZeneca employees in China, drawing comparisons to a similar situation faced by GlaxoSmithKline (NYSE:GSK) over a ...

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

The firm's commentary highlighted the ongoing investigation into certain AstraZeneca employees in China, drawing comparisons to a similar situation faced by GlaxoSmithKline (NYSE:GSK) over a decade ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

The UK's FTSE 100 index dropped to a two-month low, influenced primarily by downturns in the healthcare sector.

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...